COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE STUDIES LOCATION PRODUCT
Ability Pharmaceuticals ABTL0815 Biodrugs/ Drugs Cancer Solid Tumors 1NRP ABTL0815
Therapeutic area: Cancer
Ability Pharmaceuticals ABTL0812 Biodrugs/ Drugs Cancer Lung, Endometrial and Pancreatic Cancer 4PhII ABTL0812
Therapeutic area: Cancer
ALGENEX (Alternative Gene Expression S.L.) PCV2 vaccine Vaccines Infections Porcine Circovirus 2RP PCV2 vaccine
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) RHDV vaccine Vaccines Infections Rabbit Hemorrhagic Disease Virus 6Reg. RHDV vaccine
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) Animal Influenza Vaccines Infections - 2RP Animal Influenza
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) BDV vaccine Vaccines Infections Bovine Diarrhea Virus 1NRP BDV vaccine
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) COVID19 vaccine Vaccines Infections COVID19 vaccine with several proteins 1NRP COVID19 vaccine
Therapeutic area: Infections
Almirall Terbinafine, ALM12834 Biodrugs/ Drugs Dermatology Onychomycosis 6Reg. Terbinafine, ALM12834
Therapeutic area: Dermatology
Almirall BNZ-01 Biodrugs/ Drugs Cancer
Dermatology
Refractory cutaneous T-cell lymphoma 4PhII BNZ-01
Therapeutic area: Cancer
Dermatology
Almirall Finasteride, ALM12845 Biodrugs/ Drugs Dermatology Androgenetic Alopecia 6Reg. Finasteride, ALM12845
Therapeutic area: Dermatology
Almirall Tirbanibulin, ALM14789 Biodrugs/ Drugs Dermatology Actinic keratosis 6Reg. Tirbanibulin, ALM14789
Therapeutic area: Dermatology
Almirall Lebrikizumab Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Atopic dermatitis 5PhIII Lebrikizumab
Therapeutic area: Autoimmune & Inflammation
Dermatology
Aptatargets ApTOLL-03 Biodrugs/ Drugs Autoimmune & Inflammation Multiple Sclerosis 1NRP ApTOLL-03
Therapeutic area: Autoimmune & Inflammation
Aptatargets ApTOLL-01 Biodrugs/ Drugs Cardiovascular and circulatory systems
Central Nervous System
Acute ischemic stroke Acute coronary syndrome 3PhI ApTOLL-01
Therapeutic area: Cardiovascular and circulatory systems
Central Nervous System
APTUS Biotech AptaMnk Biodrugs/ Drugs Cancer Breast cancer treatment based on aptamers 1NRP AptaMnk
Therapeutic area: Cancer
Araclon Biotech ABvac40 Biodrugs/ Drugs Central Nervous System Alzheimer's Disease 4PhII ABvac40
Therapeutic area: Central Nervous System
Archivel Farma RUTI Vaccines Infections Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS- COV-2 Infection in Healthcare Workers 2RP Spain RUTI
Therapeutic area: Infections
Archivel Farma RUTI Vaccines Infections Safety of RUTI® Vaccination in MDR-TB Patients 4PhII Ucrania RUTI
Therapeutic area: Infections
Archivel Farma RUTI Vaccines Cancer Bladder cancer. 3PhI RUTI
Therapeutic area: Cancer
Archivel Farma RUTI® Vaccines Infections Active tuberculosis - Latent Tuberculosis 4PhII Europe and South Africa RUTI®
Therapeutic area: Infections
Arthex Biotech ARTHEx-01 Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
Myotonic dystrophy type 1 (DM1) 1NRP ARTHEx-01
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
ATRYS HEALTH NILO1 Biodrugs/ Drugs Cancer
Central Nervous System
Brain tumor and brain lesions 1NRP Spain NILO1
Therapeutic area: Cancer
Central Nervous System
Bionos Biotech SL Pytren 4Q - Scorpio Therapeutics Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Pytren 4Q se presenta como una terapia sintomática para la enfermedad huérfana de Huntington mediante la reducción de los síntomas por activación y estimulación de la autofagia y de la actividad proteasómica. Es un compuesto antioxidante, activador de la 1NRP Pytren 4Q - Scorpio Therapeutics
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Bionure BN201 Biodrugs/ Drugs Central Nervous System
Ophthalmology and optometry
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis 3PhI BN201
Therapeutic area: Central Nervous System
Ophthalmology and optometry
DIOMUNE SL IV1303 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV 2RP IV1303
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
ENTRECHEM EC-8042 iv for Triple negative breast cancer Biodrugs/ Drugs Cancer Triple negative breast cancer 2RP EC-8042 iv for Triple negative breast cancer
Therapeutic area: Cancer
ENTRECHEM EC-70124 po for TNBC Biodrugs/ Drugs Cancer Triple negative breast cancer 2RP EC-70124 po for TNBC
Therapeutic area: Cancer
ENTRECHEM Brasilicardin analogs Biodrugs/ Drugs Autoimmune & Inflammation Immunosupression 1NRP Brasilicardin analogs
Therapeutic area: Autoimmune & Inflammation
ENTRECHEM EC-70124 po for prostate cancer Biodrugs/ Drugs Cancer Castration resistant prostate cancer 2RP EC-70124 po for prostate cancer
Therapeutic area: Cancer
ENTRECHEM EC-8042 iv for liposarcoma Biodrugs/ Drugs Cancer liposarcoma myxoide 2RP EC-8042 iv for liposarcoma
Therapeutic area: Cancer
ENTRECHEM EC-70124 po for AML Biodrugs/ Drugs Cancer Acute myeloid leukemia 2RP EC-70124 po for AML
Therapeutic area: Cancer
ENTRECHEM EC-8042 iv for Ewing sarcoma Biodrugs/ Drugs Cancer Solid tumours 2RP EC-8042 iv for Ewing sarcoma
Therapeutic area: Cancer
FERRER FAB-117 Gene / Cell Therapy Central Nervous System Spinal Cord Injury 4PhII FAB-117
Therapeutic area: Central Nervous System
FERRER SP1440 Biodrugs/ Drugs Central Nervous System Small Molecular. Schizophrenia and cognitive improvement 2RP SP1440
Therapeutic area: Central Nervous System
FERRER FAB-120 Biodrugs/ Drugs Ophthalmology and optometry Diabetic Retinopathy 2RP FAB-120
Therapeutic area: Ophthalmology and optometry
FUND. PROGRESO Y SALUD FIMABIS-17003 Biodrugs/ Drugs Central Nervous System Prevention and/or treatment of mental diseases related with alcohol 1NRP FIMABIS-17003
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FISEVI-18006. Hemorrhagic cerebrospinal fluid neural stem cells Biodrugs/ Drugs Central Nervous System Treatment of infants for different neurogical disorders 2RP FISEVI-18006. Hemorrhagic cerebrospinal fluid neural stem cells
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FISEVI-15019. Piperazine derivatives as antiviral agents with increased therapeutic activity Biodrugs/ Drugs Infections Multirresistant infections 2RP FISEVI-15019. Piperazine derivatives as antiviral agents with increased therapeutic activity
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FISEVI-16001. Compositions for the treatment of ischemic ulcers and stretch marks Biodrugs/ Drugs Dermatology Treatment of ischemic ulcers and stretch marks 2RP FISEVI-16001. Compositions for the treatment of ischemic ulcers and stretch marks
Therapeutic area: Dermatology
FUND. PROGRESO Y SALUD FISEVI-19003. Furan, Thiophene or y-Lactam serterterpene tetronic acids useful as antiviral compounds against infections caused by Human Adenovirus Biodrugs/ Drugs Infections Multirresistant infections 2RP FISEVI-19003. Furan, Thiophene or y-Lactam serterterpene tetronic acids useful as antiviral compounds against infections caused by Human Adenovirus
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FIMABIS-18002 Biodrugs/ Drugs Metabolic / Endocrinology Loss weight induction mediated by browning 1NRP FIMABIS-18002
Therapeutic area: Metabolic / Endocrinology
FUND. PROGRESO Y SALUD FIBICO-14003 Gene / Cell Therapy Musculoskeletal Disorders Musculoskeletal disorders 1NRP FIBICO-14003
Therapeutic area: Musculoskeletal Disorders
FUND. PROGRESO Y SALUD FISEVI-17016. Compositions capable of modulating the stimulation of endogenous GDNF for the treatment of neurodegenerative diseases Biodrugs/ Drugs Central Nervous System Treatment of neurodegenerative diseases 2RP FISEVI-17016. Compositions capable of modulating the stimulation of endogenous GDNF for the treatment of neurodegenerative diseases
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FISEVI-19016. Novel Salicylamide derivatives for the treatment of viral infections Biodrugs/ Drugs Infections Multirresistant infections 2RP FISEVI-19016. Novel Salicylamide derivatives for the treatment of viral infections
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FIMABIS-18008 Biodrugs/ Drugs Central Nervous System Treatment for decreasing alcohol intake 1NRP FIMABIS-18008
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FIBICO-14002 Biodrugs/ Drugs Cancer Metastatic processes and resistant cancers 1NRP FIBICO-14002
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FISEVI-20001. ANTIVIRAL AGENTS FOR CORONAVIRUS Biodrugs/ Drugs Infections Treatment of COVID-19 2RP FISEVI-20001. ANTIVIRAL AGENTS FOR CORONAVIRUS
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FIMABIS-17009 Biodrugs/ Drugs Central Nervous System Depression treatment 1NRP FIMABIS-17009
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FISEVI-20002. Compounds for the treatment of sympathetic over-activation Biodrugs/ Drugs Central Nervous System Treatment of sleep apnea, heart failure, metabolic syndrome, high blood pressure and others 2RP FISEVI-20002. Compounds for the treatment of sympathetic over-activation
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FIMABIS-13001 Biodrugs/ Drugs Metabolic / Endocrinology Treatment and/or Prevention of Non-alcoholic fatty liver disease (NAFLD) 2RP FIMABIS-13001
Therapeutic area: Metabolic / Endocrinology
FUND. PROGRESO Y SALUD FIBICO Biodrugs/ Drugs Ophthalmology and optometry Others 1NRP FIBICO
Therapeutic area: Ophthalmology and optometry
FUND. PROGRESO Y SALUD FISEVI-13002 Biodrugs/ Drugs Cancer Multiple myeloma 2RP FISEVI-13002
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FIMABIS-16009 Gene / Cell Therapy Musculoskeletal Disorders Muscular regeneration 1NRP FIMABIS-16009
Therapeutic area: Musculoskeletal Disorders
FUND. PROGRESO Y SALUD FIBAO-18007 Biodrugs/ Drugs Infections Dalbavancin in the treatment of bacterial infections of the respiratory tract in children and pediatric patients 1NRP FIBAO-18007
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FIBAO-13007 Gene / Cell Therapy Cancer Cancer cells 2RP FIBAO-13007
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FIBAO-17018 Biodrugs/ Drugs Cancer Composition capable of modulating the activity of ATF4 for the treatment of cancer 1NRP FIBAO-17018
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD CABIMER-17001 Biodrugs/ Drugs Central Nervous System Treatment for injury-mediated neurodegenerative diseases 1NRP CABIMER-17001
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD FIBAO-91 Melatonine Solution Biodrugs/ Drugs Infections Sepsis 4PhII FIBAO-91 Melatonine Solution
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FIBAO-13014 Combination of Ketamine and Meperidine Biodrugs/ Drugs Autoimmune & Inflammation Mucositis 3PhI FIBAO-13014 Combination of Ketamine and Meperidine
Therapeutic area: Autoimmune & Inflammation
FUND. PROGRESO Y SALUD FIBAO-116 Biodrugs/ Drugs Analgesia & Pain Fibromyalgia 3PhI FIBAO-116
Therapeutic area: Analgesia & Pain
FUND. PROGRESO Y SALUD FIMABIS-15008 Biodrugs/ Drugs Infections Viral infection 1NRP FIMABIS-15008
Therapeutic area: Infections
FUND. PROGRESO Y SALUD CABIMER-18004 Biodrugs/ Drugs Metabolic / Endocrinology Type 2 Diabetes 1NRP CABIMER-18004
Therapeutic area: Metabolic / Endocrinology
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Advanced cell therapies Gene / Cell Therapy Blood and Lymphatic systems
Cancer
Oncology / Haematological disorders 3PhI Spain / US Advanced cell therapies
Therapeutic area: Blood and Lymphatic systems
Cancer
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Mutli-target siRNA approach Gene / Cell Therapy Autoimmune & Inflammation
Kidney and Genitourinary system
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI) 2RP Mutli-target siRNA approach
Therapeutic area: Autoimmune & Inflammation
Kidney and Genitourinary system
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) New generation of peptides Biodrugs/ Drugs Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
Chronic complications of Diabetes / Choric kidney disease 2RP New generation of peptides
Therapeutic area: Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Peptide derived from a natural compound Biodrugs/ Drugs Autoimmune & Inflammation
Metabolic / Endocrinology
Osteoporosis treatment 1NRP Peptide derived from a natural compound
Therapeutic area: Autoimmune & Inflammation
Metabolic / Endocrinology
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Advanced cell therapies Gene / Cell Therapy Ophthalmology and optometry Eye rare diseases 4PhII Spain / Europe Advanced cell therapies
Therapeutic area: Ophthalmology and optometry
Fundacion MEDINA MDN-057/MDN-058/MDN-059 Biodrugs/ Drugs Infections Gram negative infections 1NRP MDN-057/MDN-058/MDN-059
Therapeutic area: Infections
Fundacion MEDINA MDN-0090 Biodrugs/ Drugs Cancer Pancreatic Cancer 1NRP MDN-0090
Therapeutic area: Cancer
Fundacion MEDINA MDN-0145; MDN-0146 Biodrugs/ Drugs Central Nervous System Parkinson 1NRP MDN-0145; MDN-0146
Therapeutic area: Central Nervous System
Fundacion MEDINA MDN-0147; MDN-0148 & MDN-0149 Biodrugs/ Drugs Cancer Melanoma 1NRP MDN-0147; MDN-0148 & MDN-0149
Therapeutic area: Cancer
Fundacion MEDINA MDN-005 Biodrugs/ Drugs Central Nervous System
Musculoskeletal Disorders
Amyotrophic lateral sclerosis (ALS) 1NRP MDN-005
Therapeutic area: Central Nervous System
Musculoskeletal Disorders
Fundacion MEDINA MDN-088 Biodrugs/ Drugs Cancer Breast, Colon & Lung Cancer 1NRP MDN-088
Therapeutic area: Cancer
Fundacion MEDINA MDN-018 Biodrugs/ Drugs Infections Fungal Infections 1NRP MDN-018
Therapeutic area: Infections
Fundacion MEDINA MDN-0109, MDN-110, MDN-111, MDN- 112 Biodrugs/ Drugs Infections Malaria 1NRP MDN-0109, MDN-110, MDN-111, MDN- 112
Therapeutic area: Infections
Highlight Therapeutics BO-112 Biodrugs/ Drugs Cancer Solid tumors Patients with liver metastasis from colorectal cancer or gastric/gastro-esophageal junction cancer 4PhII BO-112
Therapeutic area: Cancer
Histocell HC016 Biodrugs/ Drugs Central Nervous System Acute Spinal Cord Injury 4PhII HC016
Therapeutic area: Central Nervous System
Histocell HR004 Biodrugs/ Drugs Musculoskeletal Disorders Bone Regeneration 4PhII HR004
Therapeutic area: Musculoskeletal Disorders
Histocell HR016 Biodrugs/ Drugs Respiratory and Pulmonary system Acute Lung Injury 3PhI HR016
Therapeutic area: Respiratory and Pulmonary system
Institut Quimic de Sarrià (IQS) Chondro-implant Gene / Cell Therapy Cardiovascular and circulatory systems Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure 1NRP Chondro-implant
Therapeutic area: Cardiovascular and circulatory systems
Institut Quimic de Sarrià (IQS) Cardio-implant Gene / Cell Therapy Cardiovascular and circulatory systems PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct 1NRP Cardio-implant
Therapeutic area: Cardiovascular and circulatory systems
Iproteos IPR-179 Biodrugs/ Drugs Central Nervous System Epilepsy 1NRP IPR-179
Therapeutic area: Central Nervous System
Iproteos IPR-166 Biodrugs/ Drugs Central Nervous System Cognitive Impairment associated to neurodegenerative and psychiatric diseases (schizophrenia, Parkinson's disease) 2RP Spain IPR-166
Therapeutic area: Central Nervous System
IRYCIS New compound for the treatment of isquemical stroke Biodrugs/ Drugs Central Nervous System Isquemic stroke 1NRP Spain New compound for the treatment of isquemical stroke
Therapeutic area: Central Nervous System
Laminar Pharma LP205A1 Biodrugs/ Drugs Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
Cardiovascular and Metabolic Diseases, CNS, 1NRP LP205A1
Therapeutic area: Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
Laminar Pharma LP226A1 Biodrugs/ Drugs Central Nervous System Alzheimer's Disease 2RP LP226A1
Therapeutic area: Central Nervous System
Laminar Pharma LP561A1 Biodrugs/ Drugs Cancer Glioma and other solid tumours 4PhII LP561A1
Therapeutic area: Cancer
Laminar Pharma LPA181 Biodrugs/ Drugs Central Nervous System Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company 2RP LPA181
Therapeutic area: Central Nervous System
Laminar Pharma LP204A1 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Inflammation, Cardiovascular 1NRP LP204A1
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Laminar Pharma LP30171 Biodrugs/ Drugs Cancer
Metabolic / Endocrinology
Metabolic Diseases, cancer 1NRP LP30171
Therapeutic area: Cancer
Metabolic / Endocrinology
Leukos Biotech LK-01 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
AML 3PhI LK-01
Therapeutic area: Blood and Lymphatic systems
Cancer
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System Friedreich's Ataxia 4PhII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System
Kidney and Genitourinary system
Acute X-linked Adrenoleukodystrophy (cALD; cerebral ALD) 4PhII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Kidney and Genitourinary system
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System
Metabolic / Endocrinology
Chronic X-linked Adrenoleukodystrophy (AMN; Adrenomyeloneuropathy) 5PhIII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Metabolic / Endocrinology
NATAC Retriacyl Biodrugs/ Drugs Ophthalmology and optometry Retinitis Pigmentosa 5PhIII Europe Retriacyl
Therapeutic area: Ophthalmology and optometry
Neurofix NFX91 Biodrugs/ Drugs Others Sleep disorders 1NRP NFX91
Therapeutic area: Others
Neurofix NFX88 Biodrugs/ Drugs Analgesia & Pain
Central Nervous System
Neuropathic pain 4PhII Spain NFX88
Therapeutic area: Analgesia & Pain
Central Nervous System
Neurofix NFX81 Biodrugs/ Drugs Central Nervous System Spinal Cord Injuries 2RP Spain NFX81
Therapeutic area: Central Nervous System
ONA Therapeutics ONA-1 Biodrugs/ Drugs Cancer Advanced cancer 1NRP ONA-1
Therapeutic area: Cancer
Oryzon Iadademstat (ORY-2001) selective LSD1 inhibitor Biodrugs/ Drugs Cancer AML (Elderly Unfit) - Alice Study (Combo with Azacitidine) 4PhII Iadademstat (ORY-2001) selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Multiple Sclerosis (RR & SP) - Sateen Study monotherapy 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression in BPD - Reimagine Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon HDAC-6/Other undisclosed Biodrugs/ Drugs Undisclosed 2RP HDAC-6/Other undisclosed
Therapeutic area:
Oryzon ORY-3001 - selective LSD1 inhibitor Biodrugs/ Drugs Others Non-Oncological 2RP ORY-3001 - selective LSD1 inhibitor
Therapeutic area: Others
Oryzon Iadademstat (ORY-2001) selective LSD1 inhibitor Biodrugs/ Drugs Cancer SCLC (First Line Relapsed) - Clepsidra Study (Combo with Platinum/Etoposide) 4PhII Iadademstat (ORY-2001) selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Alzheimer's Disease (Mild-Moderate) - Etheral Study monotherapy 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression is ASD - Reimagine Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression in ADHD - Reimagine Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression in AD - Reimagine-AD Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
PaloBiofarma PBF-509 Biodrugs/ Drugs Cancer
Central Nervous System
Lung Cancer 4PhII Spain PBF-509
Therapeutic area: Cancer
Central Nervous System
PaloBiofarma PBF-999 Biodrugs/ Drugs Cancer Solid Tumors 3PhI Spain PBF-999
Therapeutic area: Cancer
PaloBiofarma PBF680 Biodrugs/ Drugs Respiratory and Pulmonary system Asthma 4PhII Spain PBF680
Therapeutic area: Respiratory and Pulmonary system
PaloBiofarma PBF-677 Biodrugs/ Drugs Digestive System Colitis 4PhII Spain PBF-677
Therapeutic area: Digestive System
PaloBiofarma PBF-1129 Biodrugs/ Drugs Cancer Lung Cancer 3PhI Spain PBF-1129
Therapeutic area: Cancer
Peptomyc OMO-103 Biodrugs/ Drugs Cancer Therapy for NSCLC and breast cancer. 2RP Spain OMO-103
Therapeutic area: Cancer
PharmaMar TRABECTEDIN + Radiotherapy Biodrugs/ Drugs Cancer Sarcoma 4PhII Europe TRABECTEDIN + Radiotherapy
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Solid tumors 4PhII EU & NA LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Small Cell Lung Cancer 2nd line 4PhII NA LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) + DOXORUBICIN Biodrugs/ Drugs Cancer Small Cell lung cancer 5PhIII EU , LA & LATAM LURBINECTEDIN (PM1183) + DOXORUBICIN
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Endometrial cancer 4PhII EU & NA LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar Zepzelca Biodrugs/ Drugs Cancer Small cell Lung Cancer 2nd line 6Reg. USA Zepzelca
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Ewing Sarcoma 4PhII EU & NA LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) + CPT 11 Biodrugs/ Drugs Cancer Solid Tumors 4PhII LURBINECTEDIN (PM1183) + CPT 11
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Mesothelioma 4PhII LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar PM184 Biodrugs/ Drugs Cancer Solid tumors 4PhII EU & NA PM184
Therapeutic area: Cancer
PharmaMar PM14 Biodrugs/ Drugs Cancer Solid tumors 3PhI EU PM14
Therapeutic area: Cancer
PharmaMar TRABECTEDIN + PLD Biodrugs/ Drugs Cancer Ovarian Cancer. 5PhIII Europe TRABECTEDIN + PLD
Therapeutic area: Cancer
PharmaMar TRABECTEDIN + PLD Biodrugs/ Drugs Cancer Ovarian cancer (Japan) 3PhI Japan TRABECTEDIN + PLD
Therapeutic area: Cancer
PharmaMar TRABECTEDIN Biodrugs/ Drugs Cancer Retroperitoneal L-Sarcoma 4PhII Italy TRABECTEDIN
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Solid tumors 3PhI Japan LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer BRCA+Breast Cancer 4PhII LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
REIG JOFRE P0265 Biodrugs/ Drugs Dermatology Skin infections 5PhIII Spain, Mexico P0265
Therapeutic area: Dermatology
REIG JOFRE P0223 Biodrugs/ Drugs Dermatology Skin infection 6Reg. Spain P0223
Therapeutic area: Dermatology
Sanifit SNF472 Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Calciphylaxis 5PhIII SNF472
Therapeutic area: Cardiovascular and circulatory systems
Metabolic / Endocrinology
Sanifit SNF472 Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Peripheral Arterial Disease (dialysis) 5PhIII SNF472
Therapeutic area: Cardiovascular and circulatory systems
Metabolic / Endocrinology
SOM Biotech SOM3355 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Chorea in Huntington's disease 5PhIII Spain SOM3355
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
SOM Biotech SOM1311 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Phenylketonuria 2RP SOM1311
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
SOM Biotech SOM0061 Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
COVID-19 4PhII SOM0061
Therapeutic area: Infections
Respiratory and Pulmonary system
SOM Biotech SOM0044 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Parkinson’s disease 2RP SOM0044
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
SOM Biotech SOM0208 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Niemann-Pick 2RP SOM0208
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Sylentis siRNA / SYL1801 Biodrugs/ Drugs Ophthalmology and optometry Retina 2RP siRNA / SYL1801
Therapeutic area: Ophthalmology and optometry
Sylentis Tivanisirán / SYL1001 Biodrugs/ Drugs Ophthalmology and optometry Dry Eye Syndrome 5PhIII Tivanisirán / SYL1001
Therapeutic area: Ophthalmology and optometry
Sylentis Bamosiran / SYL040012 Biodrugs/ Drugs Ophthalmology and optometry Ocular Hypertension, Glaucoma 4PhII Bamosiran / SYL040012
Therapeutic area: Ophthalmology and optometry
VCN Biosciences VCN-11 Gene / Cell Therapy Cancer Solid Tumors 2RP VCN-11
Therapeutic area: Cancer
VCN Biosciences VCN-02 Gene / Cell Therapy Cancer Solid Tumors 1NRP VCN-02
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Pancreatic cancer 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Head & Neck Cancer 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Retinoblastoma 3PhI Spain VCN-01
Therapeutic area: Cancer
VENTER PHARMA LacTEST 2,7 g Biodrugs/ Drugs Digestive System Evaluation of hypolactasia 5PhIII LacTEST 2,7 g
Therapeutic area: Digestive System
Vivia Biotech Vivia 009 Biodrugs/ Drugs Blood and Lymphatic systems
Central Nervous System
Non Hodgkin Lymphoma, CNS 2RP Europe Vivia 009
Therapeutic area: Blood and Lymphatic systems
Central Nervous System
Vivia Biotech Vivia 011 Biodrugs/ Drugs Metabolic / Endocrinology Obesity, Diabetes 1NRP Vivia 011
Therapeutic area: Metabolic / Endocrinology
ZENDAL MTBVAC Vaccines Infections
Respiratory and Pulmonary system
MTBVAC is a live freeze dried vaccine based on a genetically attenuated strain of a clinical isolate of M. tuberculosis manufactured by BIOFABRI. MTBVAC is now in Phase 2a in newborns infants and a Phase2a in BCG-vaccinated adults in South Africa 4PhII MTBVAC
Therapeutic area: Infections
Respiratory and Pulmonary system